Regent Pacific Group Limited

Overview

Regent Pacific Group Limited is an investment company specializing in the healthcare and life sciences sectors. The company focuses on growth and value-led investments in these areas, aiming to build a powerful portfolio of investments that can be commercialized through out-licensing to strategic pharmaceutical partners. This strategy is designed to create shareholder value through strategic acquisitions and returning surplus capital to shareholders. The company's operations are divided into two main segments: Biopharma and Corporate Investment. In the Biopharma segment, Regent Pacific is involved in the research, development, manufacture, marketing, and sale of pharmaceutical products, particularly those targeting urological disorders. Additionally, the company is engaged in the development of artificial intelligence systems designed to track the rate of aging at various levels, including molecular, cellular, tissue, organ, system, physiological, and psychological. The Corporate Investment segment focuses on investing in both listed and unlisted corporate entities, providing management services, and seeking opportunities that align with the company's strategic objectives. Regent Pacific Group Limited was formerly known as Endurance RP Limited and changed its name to Regent Pacific Group Limited in July 2023. The company was founded in 1991 and is headquartered in Central, Hong Kong. As of the latest available information, the company employs 17 individuals. The Chief Executive Officer and Executive Director is Jamie Alexander Gibson, who joined the group in April 1996 and has been serving in his current role since January 2002. The company's stock is listed on the Hong Kong Stock Exchange under the ticker symbol 0575. Please note that the information provided is based on the latest available data and may be subject to change. For the most current information, it is recommended to visit the company's official website or consult official financial disclosures.